AKERO THERAPEUTICS,

AKRO
Delayed Nasdaq - 04:00 2022-12-06 pm EST
41.54 USD -5.63%

Turn to zoom
Prev.41.54000000
Open43.91000000
High44.22000000
Low40.66000000
Volume504 619
Latest news
4d ago
4d ago
11/14
11/10
Chart AKERO THERAPEUTICS, INC.
Technical analysis trends
Short TermMid-TermLong Term
TrendNeutralBullishBullish
Resistance46,546,545,8
Spread/Res.-11%-11%-9,4%
Spread/Supp.8,8%106%109%
Support38,220,219,9
Financials
Sales 2022 - - -
Net income 2022 -125 M - -
Net cash 2022 307 M - -
P/E ratio 2022 -12,9x
Yield 2022 -
Capitalization 1 943 M 1 943 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 35
Free-Float 90,2%
Company
Akero Therapeutics Inc. is a clinical-stage company that develops transformational treatments for patients with serious metabolic diseases. The Company is engaged to treat non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate, efruxifermin (EFX),...
Sector :
Bio Therapeutic Drugs
Calendar :
2023-03-20 Earnings Release
Trading Rating :
Investor Rating : -

Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 41,54 $
Average target price 50,33 $
Spread / Average Target 21,2%